This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akili Temettü

Temettü kriter kontrolleri 0/6

Akili şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.62
Gelecekteki Temettü Verimi	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Akili surges 21% as Singapore investment firms take joint stake

Aug 26

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: AKLI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: AKLI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Akili Piyasaya Karşı Temettü Getirisi

AKLI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (AKLI)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Healthcare Services)	1.0%
Analist tahmini (AKLI) (3 yıla kadar)	0%

Önemli Temettü: AKLI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, AKLI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: AKLI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: AKLI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

This company has been acquired

Akili Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Report Q1, 2024 Results on May 14, 2024

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

New major risk - Share price stability

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Price target increased by 25% to US$5.00

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akili Receives Non-Compliance Notice from Nasdaq

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

Price target decreased by 25% to US$3.00

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%

Consensus revenue estimates decrease by 44%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

Consensus revenue estimates increase by 32%, EPS downgraded

Price target decreased by 8.3% to US$3.44

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 26%, EPS upgraded

Full year 2022 earnings released: US$0.10 loss per share (vs US$106 loss in FY 2021)

Akili, Inc. announces Pivotal Trial of Endeavorrx in Adolescents with Adhd Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. Announces the Appointment of Scott Kollins, Ph.D., as Chief Medical Officer, Effective December 1, 2022

Consensus forecasts updated

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$35.91 (vs US$15.61 loss in 3Q 2021)

Akili, Inc. Announces Board Changes

Akili surges 21% as Singapore investment firms take joint stake

Second quarter 2022 earnings released

No independent directors

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin